Interaction of Calcium Supplementation and Nonsteroidal Anti-inflammatory Drugs and the Risk of Colorectal Adenomas

• Published in: Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2005-10, Vol.14 (10), p.2353-2358
• Main Authors: GRAU, Maria V, BARON, John A, BANY, Elizabeth L, SANDIER, Robert S, HAILE, Robert W, MANDEL, Jack S, COLEL, Bernard F
• Format: Article
• Language: English
• Subjects: Adenoma - prevention & control; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Aspirin - administration & dosage; Aspirin - therapeutic use; Biological and medical sciences; Calcium - administration & dosage; Calcium - therapeutic use; calcium supplementation; Calcium, Dietary - administration & dosage; Calcium, Dietary - therapeutic use; colorectal adenomas; Colorectal Neoplasms - prevention & control; Drug Synergism; Female; Gastroenterology. Liver. Pancreas. Abdomen; Gastrointestinal cancers: colorectal; Humans; Male; Medical sciences; Middle Aged; Multicenter Studies as Topic; NSAIDS; Randomized Controlled Trials as Topic; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tumors
• ISSN: 1055-9965; 1538-7755
• DOI: 10.1158/1055-9965.EPI-05-0003

Background: Calcium and aspirin have both been found to be chemopreventive against colorectal neoplasia. However, the joint effect of the two agents has not been well investigated. Methods: To explore the separate and joint effects of calcium and aspirin/nonsteroidal anti-inflammatory drugs (NSAID), we used data from two large randomized clinical trials among patients with a recent history of colorectal adenomas. In the Calcium Polyp Prevention Study, 930 eligible subjects were randomized to receive placebo or 1,200 mg of elemental calcium daily for 4 years. In the Aspirin/Folate Polyp Prevention Study, 1,121 eligible subjects were assigned to take placebo, 81 mg of aspirin, or 325 mg of aspirin daily for 3 years. In each study, subjects completed a validated food frequency questionnaire at enrollment and were asked periodically about medications and supplements used. Recurrent adenomas and advanced adenomas were the end points considered. We used generalized linear models to assess the separate and combined effects of aspirin (or NSAIDs) and calcium supplementation (or dietary calcium) and the interactions between these exposures. Results: In the Calcium Trial, subjects randomized to calcium who also were frequent users of NSAIDs had a reduction of risk for advanced adenomas of 65% [adjusted risk ratio (RR), 0.35; 95% confidence interval (95% CI), 0.13-0.96], and there was a highly significant statistical interaction between calcium treatment and frequent NSAID use ( P interaction = 0.01). Similarly, in the Aspirin Trial, 81 mg aspirin and calcium supplement use together conferred a risk reduction of 80% for advanced adenomas (adjusted RR, 0.20; 95% CI, 0.05-0.81); there was a borderline significant statistical interaction between the two treatments ( P interaction = 0.09). In this trial, we found similar trends when we considered baseline dietary calcium intake instead of calcium supplements. For all adenomas considered together, the interactive patterns were not consistent. Conclusion: Data from two different randomized clinical trials suggest that calcium and NSAIDs may act synergistically to lower the risk of advanced colorectal neoplastic polyps.